Suppression of mammary gland tumorigenesis in diabetic rats

被引:11
作者
Cocca, C
Gutiérrez, A
Núñez, M
Croci, M
Martín, G
Cricco, G
Rivera, E
Bergoc, R
机构
[1] Univ Buenos Aires, Sch Pharm & Biochem, Radioisotopes Lab, RA-1113 Buenos Aires, DF, Argentina
[2] Inst Immunooncol, Buenos Aires, DF, Argentina
来源
CANCER DETECTION AND PREVENTION | 2003年 / 27卷 / 01期
关键词
mammary tumors; multistep carcinogenesis; rats; IGF-1; insulin; diabetes;
D O I
10.1016/S0361-090X(02)00130-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to compare mammary gland tumorigenesis in diabetic and non-diabetic rats. streptozotocin and N-nitroso-N-methylurea were used to induce. diabetes and mammary tumors, respectively. A suppression of mammary carcinogenesis in diabetic rats was shown by a longer latency period, a lower number of tumors per animal and a smaller final tumor volume. An 84% of the lesions developed in diabetic animals were benign tumors. Eighty day-old diabetic rats had significantly lower plasma levels of total-IGF-I and insulin versus non-diabetic rats. We postulate that the decrease in the total IGF-I and insulin levels during the promotion phase of carcinogenesis in this model plays an important role in retarding the tumor development in diabetic animals and in favoring the development of benign mammary lesions. (C) 2002 International Society for Preventive Oncology. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:37 / 46
页数:10
相关论文
共 50 条
  • [1] Agresti A., 1990, Analysis of categorical data
  • [2] BASEDOVSKY H, 2000, INT J CANCER, V86, P446
  • [3] BASERGA R, 1995, CANCER RES, V55, P249
  • [4] Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo
    Chernicky, CL
    Yi, LJ
    Tan, HQ
    Gan, SU
    Ilan, J
    [J]. CANCER GENE THERAPY, 2000, 7 (03) : 384 - 395
  • [5] Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden
    Clauson, PG
    Brismar, K
    Hall, K
    Linnarsson, R
    Grill, V
    [J]. SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1998, 58 (04) : 353 - 360
  • [6] An experimental model of diabetes and cancer in rats
    Cocca, C
    Martin, G
    Rivera, E
    Davio, C
    Cricco, G
    Lemos, B
    Fitzsimons, C
    Gutierrez, A
    Levin, E
    Levin, R
    Croci, M
    Bergoc, RM
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (06) : 889 - 894
  • [7] COCCA C, 1995, MEDICINA, V55, P492
  • [8] COHEN ND, 1979, CANCER RES, V34, P3245
  • [9] TOXICOLOGICAL AND PATHOLOGICAL APPLICATIONS OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA), A NOVEL ENDOGENOUS MARKER FOR CELL-PROLIFERATION
    DIETRICH, DR
    [J]. CRITICAL REVIEWS IN TOXICOLOGY, 1993, 23 (01) : 77 - 109
  • [10] EXPRESSION OF INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEINS IN HUMAN BREAST-CANCER CORRELATES WITH ESTROGEN-RECEPTOR STATUS
    FIGUEROA, JA
    JACKSON, JG
    MCGUIRE, WL
    KRYWICKI, RF
    YEE, D
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, 52 (02) : 196 - 205